Holen Sie sich die Stockscreener-App
1.17
6.40%
-0.08
Handel nachbörslich:
1.20
0.03
+2.56%
Phio Pharmaceuticals Corp Aktie (PHIO) Neueste Nachrichten
Sidoti Boosts Earnings Estimates for Phio Pharmaceuticals - Defense World
PHIO: RNA therapy for skin cancer shows 85% response and no toxicities, advancing to pivotal trials - TradingView
Phio Pharmaceuticals to Present at the Life Sciences Investor Forum on March 12, 2026, 11 AM EDT - TMX Newsfile
Cancer gene-silencing trial shows 65% response in Phio study - Stock Titan
How Phio Pharmaceuticals Corp. stock compares to industry benchmarksBuy Signal & High Accuracy Trade Signal Alerts - Naître et grandir
EV Market: Is Phio Pharmaceuticals Corp being accumulated by smart moneyJuly 2025 Sector Moves & Free Accurate Trade Setup Notifications - baoquankhu1.vn
Phio Pharmaceuticals Reports 2025 Year-End Financial Results and Business Update - Yahoo Finance
Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series - marketscreener.com
Phio cancer drug PH-762 posts 65% response; CEO hosts live Q&A - Stock Titan
PHIO Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Cancer Biotech Phio Pharmaceuticals Stock Surges As Trial Shows Tumor Clearance At Highest Dose In Skin Cancer Patients - Sahm
PHIO Should I Buy - Intellectia AI
PHIO Technical Analysis & Stock Price Forecast - Intellectia AI
Phio Pharmaceuticals Corp. Selected as B2i Digital Featured Company - Weekly Voice
Phio Pharmaceuticals Reports Promising Phase 1b Results for Skin Cancer Therapy, Plans FDA Submission for 2026 - citybuzz -
Phio Pharmaceuticals Aligns Leadership Team to Support Next Stage Development of PH-762 and Advancement of PH-894 - The Courier-Journal
Is Phio Pharmaceuticals Corp. stock trending bullish2025 Major Catalysts & Advanced Technical Analysis Signals - mfd.ru
Phio Pharmaceuticals Boosts CEO Severance and Incentive Compensation - TipRanks
CEO contract changes at Phio (NASDAQ: PHIO) lift bonus target - Stock Titan
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
CVI and Heights disclose 9.9% Phio (PHIO) stake based on warrant holdings - Stock Titan
Will Phio Pharmaceuticals Corp. benefit from rising consumer demandWeekly Investment Report & Advanced Swing Trade Entry Alerts - mfd.ru
What are Phio Pharmaceuticals Corp.’s growth leversInsider Buying & AI Forecast for Swing Trade Picks - mfd.ru
DealFlow Discovery Conference: Opportunities Unveiled - timothysykes.com
Can Phio Pharmaceuticals Corp. lead its sector in growthEarnings Growth Summary & Growth Focused Stock Reports - mfd.ru
Phio Pharmaceuticals Corp. (PHIO) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
PHIO Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
12 Health Care Stocks Moving In Friday's Intraday Session - Benzinga
Aug Closing: Is Phio Pharmaceuticals Corp. being accumulated by smart moneyJuly 2025 Reactions & Real-Time Chart Breakout Alerts - mfd.ru
What's Going On With Tiny Cancer Biotech Phio Pharmaceuticals On Thursday? - Benzinga
Best Penny Stocks To Watch Now – February 10th - Defense World
DealFlow Events Sets Stage for PEIO Stock Momentum - StocksToTrade
Phio reports positive results from PH-762 skin cancer trial By Investing.com - Investing.com Australia
Phio Pharmaceuticals (PHIO) stock rises premarket as new PH-762 skin cancer data keeps traders circling - TechStock²
Phio reports positive results from PH-762 skin cancer trial - Investing.com South Africa
PHIO: HC Wainwright & Co. Reiterates Buy Rating with $14 Price T - GuruFocus
Phio Pharmaceuticals Corp. (PHIO) stock: jumps 43% as cancer trial shows strong safety and response rates - parameter.io
DealFlow Conference Set to Boost Over 100 Companies - StocksToTrade
Phio Pharmaceuticals stock soars after strong cancer treatment results - Investing.com
DealFlow Discovery Conference Unveils Corporate Opportunities - timothysykes.com
Phio Pharmaceuticals Reports Positive PH-762 Phase 1b Safety Results - TipRanks
Phio Pharmaceuticals Corp Announces Positive Phase 1b Trial Results for PH-762 - TradingView
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
Top PH-762 skin cancer dose triggers 85% tumor response in Phio trial - Stock Titan
Retail Surge: Does Phio Pharmaceuticals Corp offer margin of safety2025 Growth vs Value & Free Technical Confirmation Trade Alerts - baoquankhu1.vn
Can Phio Pharmaceuticals Corp. sustain its profitability2025 Momentum Check & Long-Term Growth Portfolio Plans - mfd.ru
Phio Pharmaceuticals Announces Participation in Third Annual DealFlow Discovery Conference - TMX Newsfile
Cancer drug developer Phio joins free Atlantic City investor discovery event - stocktitan.net
Aug PreEarnings: Is Hennessy Capital Investment Corp VII stock a top performer YTDJuly 2025 Macro Moves & Consistent Return Investment Signals - baoquankhu1.vn
Phio Pharmaceuticals reports 70% response rate in skin cancer trial By Investing.com - Investing.com India
Phio Reports Positive Phase 1b PH-762 Skin Cancer Data - TipRanks
Phio Pharmaceuticals Corp Announces Key Tumor Response Data from PH-762 Trial - TradingView
0.48%
1.21%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):